To demonstrate the role of JAK in the anti-inflammatory effects of IFN-β on CF, the CF were stimulated with ruxolitinib (500 nM), a selective JAK inhibitor, for 30 min. The gene discussed is IFNB1; the disease is cystic fibrosis.